Cebranopadol Solid Dispersion for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cebranopadol-based pharmaceutical compositions face challenges with solubility, bioavailability, and content uniformity due to its poor solubility and tendency to undergo solid state changes, requiring strict temperature control and leading to undesirable side effects and regulatory issues, especially in hot climates.
Innovation Solution
A pharmaceutical composition comprising dissolved cebranopadol in an organic solvent with a high boiling point, combined with a solid carrier, which maintains cebranopadol in a dissolved state and prevents solid state transformations, allowing for stable and processable oral dosage forms without the need for temperature control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cebranopadol is formulated in dispersed or dissolved form in liquid core surrounded by encapsulating material (SEDDS), then solubility and bioavailability are improved, but production complexity increases and gastrointestinal side effects occur
Solution Approach 1:
The patent extracts the liquid core and encapsulating material from the formulation, replacing them with a solid dispersion system where cebranopadol is dispersed in a solid carrier matrix. This eliminates the complex SEDDS production process while maintaining solubility benefits through the solid dispersion approach.
Solution Approach 2:
The patent changes the physical state parameter from liquid core to solid dispersion system. By transforming the formulation from liquid to solid state, it simplifies production while maintaining the drug's solubility and bioavailability characteristics through the solid carrier matrix.
2Ease of manufacture
If crystalline polymorphs are used in dosage forms, then manufacturing is simplified, but solid state changes occur requiring strict temperature control
Solution Approach 1:
The patent performs preliminary action by converting cebranopadol to an amorphous state before dosage form manufacturing. This pre-transformation prevents subsequent solid state changes and polymorphic conversions that would otherwise require temperature control during storage and handling.
Solution Approach 2:
The patent changes the physical state parameter from crystalline polymorph to amorphous form. This parameter change eliminates the issue of polymorphic conversions and solid state changes, providing compositional stability without requiring strict temperature control while maintaining ease of manufacture.
3Object-generated harmful factors
If cebranopadol is applied in very small amounts to achieve therapeutic effect, then side effects are reduced, but content uniformity in dosage forms becomes difficult to achieve
Solution Approach 1:
The patent applies local quality by creating a homogeneous distribution of cebranopadol throughout the solid carrier matrix. The drug is dispersed at molecular or microparticulate level within the carrier, ensuring uniform local concentration and thus achieving content uniformity in the final dosage form while maintaining low total drug amounts.
Solution Approach 2:
The patent uses a composite material system consisting of cebranopadol dispersed in a solid carrier matrix. This composite approach allows the low-dose drug to be uniformly distributed within the carrier material, achieving both low side effects and high content uniformity through the synergistic combination of drug and carrier properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides improved dissolution and pharmacokinetic properties, enhanced processability, and consistent therapeutic effects, ensuring rapid pain relief with long-lasting benefits, while avoiding the use of encapsulated liquid cores or polymorphs, thus overcoming previous formulation drawbacks.
Implementation Method 1
comprising dissolved cebranopadol, organic solvent with a high boiling point
Implementation Method 2
cebranopadol may adhere to said carrier or is preferably adsorbed on said carrier in dissolved form
Implementation Method 3
organic solvent with a high boiling point... organic solvent with a boiling point of 110 to 350°C at 1013 mbar
Data Source
Figure A-1
Figure A-2
Figure A-3
AI summary
The present invention relates to a composition comprising cebranopadol in dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising cebranopadol in dissolved form and to the corresponding process of producing an oral dosage form containing the composition of the invention.